Antiangiogenic Properties of Gold Nanoparticles

Priyabrata Mukherjee(Mayo Clinic), Resham Bhattacharya(Mayo Clinic), Ping Wang(Beth Israel Deaconess Medical Center), Ling Wang(Mayo Clinic), Sujit Basu(Mayo Clinic), Janice A. Nagy(Beth Israel Deaconess Medical Center), Anthony Atala(Forest Institute), Debabrata Mukhopadhyay(Mayo Clinic), Shay Söker(Forest Institute)
Clinical Cancer Research
May 1, 2005
Cited by 465

Abstract

Here, we report an intrinsic property of gold nanoparticles (nanogold): they can interact selectively with heparin-binding glycoproteins and inhibit their activity. Gold nanoparticles specifically bound vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-165 and basic fibroblast growth factor, two endothelial cell mitogens and mediators of angiogenesis resulting in inhibition of endothelial/fibroblast cell proliferation in vitro and VEGF-induced permeability as well as angiogenesis in vivo. In contrast, nanogold did not inhibit VEGF-121 or epidermal growth factor, two non-heparin-binding growth factors, mediated cell proliferation. Gold nanoparticles significantly inhibited VEGF receptor-2 phosphorylation, intracellular calcium release, and migration and RhoA activation in vitro. These results report for the first time a novel property of gold nanoparticles to bind heparin-binding proteins and thereby inhibit their subsequent signaling events.


Related Papers

No related papers found

Powered by citation graph analysis